Abstract
Histone deacetylase inhibitors are nowadays considered as promising anti-cancer drugs, as they interfere with several key steps of tumor development and progression, both in vitro and in vivo. Less attention has been paid to their impact on cell junctions. Nevertheless, cell junctions are gatekeepers in the management of tissue homeostasis, and their aberrant expression and functioning is observed in all aspects of cancer biology. The present review provides a state of the art of the current knowledge concerning the effects of histone deacetylase inhibitors on cell junctions. Besides an updated theoretical basis, we also exemplify its actual relevance in cancer therapy.
Keywords: histone deacetylase inhibitor, adherens junction, tight junction, gap junction, (hemi)desmosome, focal adhesion
Current Drug Targets
Title: Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Volume: 7 Issue: 6
Author(s): Mathieu Vinken, Papeleu Peggy, Rogiers Vera and Vanhaecke Tamara
Affiliation:
Keywords: histone deacetylase inhibitor, adherens junction, tight junction, gap junction, (hemi)desmosome, focal adhesion
Abstract: Histone deacetylase inhibitors are nowadays considered as promising anti-cancer drugs, as they interfere with several key steps of tumor development and progression, both in vitro and in vivo. Less attention has been paid to their impact on cell junctions. Nevertheless, cell junctions are gatekeepers in the management of tissue homeostasis, and their aberrant expression and functioning is observed in all aspects of cancer biology. The present review provides a state of the art of the current knowledge concerning the effects of histone deacetylase inhibitors on cell junctions. Besides an updated theoretical basis, we also exemplify its actual relevance in cancer therapy.
Export Options
About this article
Cite this article as:
Vinken Mathieu, Peggy Papeleu, Vera Rogiers and Tamara Vanhaecke, Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts, Current Drug Targets 2006; 7 (6) . https://dx.doi.org/10.2174/138945006777435281
DOI https://dx.doi.org/10.2174/138945006777435281 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets Editorial [Hot Topic: Cancer Genetics (Guest Editor: Anirban Maitra)]
Current Molecular Medicine Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer
Current Cancer Drug Targets Dimethylaminoparthenolide, A Water Soluble Parthenolide, Suppresses Lung Tumorigenesis Through Down-Regulating the STAT3 Signaling Pathway
Current Cancer Drug Targets Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design Multiple Roles of Transient Receptor Potential (TRP) Channels in Inflammatory Conditions and Current Status of Drug Development
Current Topics in Medicinal Chemistry Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery QSAR and the Prediction of T-Cell Epitopes
Current Proteomics Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry The Disulfide Analogues of Isophosphoramide Mustard for Anticancer Therapy
Letters in Drug Design & Discovery The Post Hoc Use of Randomised Controlled Trials to Explore Drug Associated Cancer Outcomes: Methodological Challenges
Current Drug Safety The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Synthesis and Biological Evaluation of 2-, 3-, and 4-Acylaminocinnamyl-Nhydroxyamides as Novel Synthetic HDAC Inhibitors
Medicinal Chemistry Short-Term Intra-Nasal Erythropoietin Administration with Low Sialic Acid Content is without Toxicity or Erythropoietic Effects
Current Neurovascular Research Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets New Therapeutic Strategies for Castration-Resistant Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Carbonyl-Scavenging Drugs & Protection Against Carbonyl Stress-Associated Cell Injury
Mini-Reviews in Medicinal Chemistry